A Study on the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 to 49 Years and Infants Born to the Vaccinated Mothers
NCT ID: NCT04980391
Last Updated: 2025-04-20
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
384 participants
INTERVENTIONAL
2021-08-03
2023-05-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Following a recommendation from the Independent Data Monitoring Committee of NCT04605159 (RSV MAT 009), GSK made the decision to stop enrolment and vaccination in the study. Ongoing study participants at that time continued to be monitored as part of the study.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers
NCT04605159
A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control
NCT05705440
A Phase III Study to Assess the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response and Safety of RSV Maternal Vaccine When Given Alone or Co-administered With GSK's Influenza D-QIV Vaccine in Healthy Non-pregnant Women.
NCT05045144
A Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.
NCT04424316
A Study to Evaluate the Safety and Immune Response to an Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Females From 9 to 49 Years of Age
NCT05169905
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
RSV_MAT Group
Maternal participants randomized to the RSV\_MAT Group received a single dose of the RSV MAT vaccine administered, between 24 and 36 weeks of gestation, at Day 1 in this study.
RSV MAT
Single dose of the RSV MAT vaccine reconstituted with NaCl solution, administered intramuscularly in the non-dominant arm, at Day 1.
Control Group
Maternal participants randomized to the Control Group received a single dose of Placebo administered, between 24 and 36 weeks of gestation, at Day 1 in this study.
Placebo
Single dose of placebo, administered intramuscularly in the non-dominant arm, at Day 1.
RSV_MAT Group-Infant
This group consisted of infants born to mothers (from RSV\_MAT Group-Mother) who received a single dose of RSV MAT vaccine during pregnancy.
No interventions assigned to this group
Control Group-Infant
This group consisted of infants born to mothers (from Control Group-Mother) who received a single dose of placebo during pregnancy.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
RSV MAT
Single dose of the RSV MAT vaccine reconstituted with NaCl solution, administered intramuscularly in the non-dominant arm, at Day 1.
Placebo
Single dose of placebo, administered intramuscularly in the non-dominant arm, at Day 1.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants who can and will comply with the requirements of the protocol.
* Participants and LARs who give written or witnessed/thumb printed informed consent after the study has been explained according to local regulatory requirements, and before any study specific procedures are performed. The informed consent given at screening should either:
* include consent for both the maternal participant's participation\* and participation of the infant after the infant's birth, or
* include consent for the maternal participant's participation\* and expressed willingness to consider permitting the infant to take part after the infant's birth (if local regulations/guidelines require parent(s) to provide an additional informed consent after the infant's birth).
* both mother and father should consent if local regulations / guidelines require it.
* Pre-pregnancy Body Mass Index (based on participant's report) 18.5 to 39.9 kg/m\^2, inclusive.
* Healthy adolescent pregnant women, 15 to 17 YOA, inclusive, at the time of study intervention administration.
OR
* Pregnant women, 18 to 49 YOA, inclusive, at the time of study intervention administration with:
* HIV infection AND/OR
* Obstetric complications or risk factors during the current pregnancy, where the expectant management of the pregnancy is possible and without evidence of non-reassuring fetal status (only cases for which fetal heart rate can be ascertained) as follows:
* Gestational diabetes, well-controlled on medications (with or without diet or exercise)
* Gestational hypertension, well-controlled on diet or medications below 160/110 mmHg.
* Pre-eclampsia without severe features (i.e. eclampsia, severe hypertension \[\>160/110 mmHg\], organ dysfunction, unstable or complicated by \[HELLP\] syndrome).
* Fetal Growth Restriction in singleton pregnancies, with normal umbilical artery Doppler and estimated fetal weight 3 to 10th percentile for gestational age.
* History of threatened preterm labor in the current pregnancy, with no cervical dilation greater than 2 cm or effacement exceeding 50%, and/or no progressive change in cervical dilation or effacement detected by serial examinations, when maternal participant is asymptomatic
* Uncomplicated twin gestation.
* Pregnant females at 24\^0/7 to 36\^0/7 weeks of gestation at the time of study intervention administration (Day 1), as established by:
* Last menstrual period (LMP) date corroborated by first or second trimester ultrasound examination (U/S) (i.e. at or before 28 weeks of gestation).
* First or second trimester U/S only, if LMP is unknown/uncertain.
* Certain LMP, corroborated by an U/S performed after 28 weeks of gestation is also acceptable.
The level of diagnostic certainty of the gestational age should be established by using the Global Alignment of Immunization Safety Assessment in pregnancy (GAIA) gestation age assessment tool
* Participants who are willing to provide cord blood.
* Willing to have their offspring followed-up after delivery for a period of 12 months.
* Participants who do not plan to give their offspring for adoption or place the child in care.
Infant participants
* Live-born from the study pregnancy.
* If required per local regulations / guidelines, re-signed (confirmed) written or witnessed/thumb printed informed consent for study participation of the infant obtained from the infant's mother and/or father and/or LAR, before performing any infant study specific procedure. To comply with RTI surveillance and other protocol required procedures that begin immediately after birth: if written consent cannot be provided by the parent(s)/LAR(s) readily post-birth, verbal consent - if permitted per local regulation -- may be sought from the parent(s) / LAR(s) instead. Verbal consent should be documented in the source data by the investigator or delegate. The parent(s) / LAR(s) will provide additional, written informed consent by (or before) Visit 2-NB.
Exclusion Criteria
* History of any reaction or hypersensitivity likely to be exacerbated by any component of the study intervention.
* Hypersensitivity to latex.
* Any pre-existing medical conditions or obstetric complications in the current pregnancy that, are poorly controlled and/or with clinical evidence of a non-reassuring fetal status and/or are likely to result in delivery within 7 days after study intervention administration and/or when the timing of planned delivery is within 7 days after study intervention administration and/or acute conditions requiring immediate medical attention for maternal stabilization and/or treatment.
* A multiple pregnancy with 3 or more fetuses.
* Complicated twin gestation.
* Placenta Accreta Spectrum, including placenta increta, percreta, and accreta.
* Fetal structural defects or genetic abnormalities that affect (or are likely to affect) fetal health or survival during the first year of life.
* Known or suspected impairment of the immune system or immunodeficiency syndrome other than HIV.
* Lymphoproliferative disorder or malignancy within 5 years before study dose administration.
* Any illness of the mother or conditions of the fetus that, may substantially interfere with the maternal participant's ability to comply with study procedures, or could increase the risks to the mother or the fetus, or could preclude the evaluation of the participant's data.
* Any other clinical condition that, might pose additional risk to the participant due to participation in the study, as determined by medical history, physical examination or laboratory screening tests.
* Women with any diagnosis, condition, treatment, or other factor that, has the potential to affect or confound assessments of immunogenicity or safety
* Any conditions which, in the investigator's opinion, would increase the risks of study participation to the unborn infant.
Prior/Concomitant therapy
* Prior receipt of an RSV maternal vaccine.
* Use of any investigational or non-registered product other than the study intervention(s) during the period beginning:
* For a drug, vaccine or medical device: 29 days before the dose of study intervention(s) (Day -28 to Day 1), or their planned use during the study period.
* For immunoglobulins: 90 days before the dose of study intervention(s), or their planned use during the study period.
The exception to this is investigational products administered in the setting of a pandemic. Administration in this case should respect the same period outlined above prior to study intervention administration, but may be allowed following delivery.
* Planned administration/administration of a vaccine not foreseen by the study protocol in the period starting 29 days before the study Day 1 and ending at delivery, with the exception of seasonal influenza vaccines, tetanus vaccines, dTpa/Tdap - alone vaccines, dTpa/Tdap vaccines that also contain other antigens and Hepatitis B vaccines, all of which may be administered according to standard of care ≥ 15 days before or after study intervention (Day 1).
* Receipt of blood or plasma products or immunoglobulin, from 90 days before study intervention administration, or planned receipt through delivery, with the exception of Rho(D) immunoglobulin, which can be given at any time. In that sense, COVID-19 vaccines may be allowed, when administered ≥ 15 days before or after study vaccination.
* Administration of immune-modifying therapy within 6 months before study intervention administration, or planned administration through delivery, except if it is part of management of HIV infection.
Prior/Concurrent clinical study experience
• Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational intervention.
Other exclusions
* Alcoholism or substance use disorder within the past 24 months based on the presence of 2 or more of the following abuse criteria: hazardous use, social/interpersonal problems related to use, neglect of major roles to use, withdrawal, tolerance, use of larger amounts or longer, repeated attempts to quit or control use, much time spent using, physical or psychological problems related to use, activities given up to use, craving.
* A local condition that precludes injection of the study vaccine/product or precludes assessment of local (administration site) reactogenicity.
* Consanguinity of maternal participant and her partner.
* Any study personnel or their immediate dependents, family, or household members.
Infant participants
* Concurrently participating in another clinical trial, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational vaccine/product.
* Any condition which, would increase the risks of study participation to the infant.
* Child in care.
15 Years
49 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Birmingham, Alabama, United States
GSK Investigational Site
Dothan, Alabama, United States
GSK Investigational Site
Mobile, Alabama, United States
GSK Investigational Site
Phoenix, Arizona, United States
GSK Investigational Site
Covington, Louisiana, United States
GSK Investigational Site
Lafayette, Louisiana, United States
GSK Investigational Site
Slidell, Louisiana, United States
GSK Investigational Site
Missoula, Montana, United States
GSK Investigational Site
Arlington, Texas, United States
GSK Investigational Site
Austin, Texas, United States
GSK Investigational Site
Fort Worth, Texas, United States
GSK Investigational Site
Grapevine, Texas, United States
GSK Investigational Site
Houston, Texas, United States
GSK Investigational Site
League City, Texas, United States
GSK Investigational Site
Plano, Texas, United States
GSK Investigational Site
Weatherford, Texas, United States
GSK Investigational Site
Caxias do Sul, , Brazil
GSK Investigational Site
RibeirAo PretoSP, , Brazil
GSK Investigational Site
Santa Maria, , Brazil
GSK Investigational Site
Halifax, Nova Scotia, Canada
GSK Investigational Site
Montreal, Quebec, Canada
GSK Investigational Site
Helsinki, , Finland
GSK Investigational Site
Bhubaneswar, , India
GSK Investigational Site
Mysuru, , India
GSK Investigational Site
Messina, , Italy
GSK Investigational Site
Perugia, , Italy
GSK Investigational Site
Prato, , Italy
GSK Investigational Site
Panama City, , Panama
GSK Investigational Site
Soweto Gauteng, , South Africa
GSK Investigational Site
Boadilla Del Monte Madrid, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Madrid, , Spain
GSK Investigational Site
Málaga, , Spain
GSK Investigational Site
TorrejOn Ardoz Madrid, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021-000994-96
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
214725
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.